



11/B
gnd
1/10/03 N.E.
PATE

RECEIVED
DEC 04 2002
TECH CENTER 1600/2300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. Hellstrand, et al.

Appl. No. : 09/616,622

Filed : July 14, 2000

For : **ACTIVATION AND
PROTECTION OF
CYTOTOXIC
LYMPHOCYTES USING A
REACTIVE OXYGEN
METABOLITE INHIBITOR**

Examiner : G.R. Ewoldt, Ph.D.

) Group Art Unit 1644

) I hereby certify that this correspondence and
) marked attachments are being deposited with
) United States Postal Service as first-class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. Box 2327,
) Arlington, VA 22202, on

) November 25, 2002

) (Date)

) James J. Muller III, Ph.D., Reg. No. 44,957

AMENDMENT AND RESPONSE AFTER FINAL

United States Patent and Trademark Office
P.O. Box 2327, Arlington, VA 22202

Dear Sir:

This is in response to the Office Action mailed July 26, 2002 (Paper No. 10) for the above-referenced patent application. Reconsideration of the application in view of the amendments and remarks below is respectfully requested.

IN THE CLAIMS

✓
Please cancel Claim 13, without prejudice.

Please amend Claims 1, 9 and 10 to read as follows:

1. (Twice Amended) A method for protecting NK cells and cytotoxic T lymphocytes from oxidative inhibition in the presence of monocytes (MO), comprising:
- identifying a patient in need of enhanced NK cell and cytotoxic T lymphocyte activity; and
 - administering to the patient a composition comprising an amount of diphenylene iodonium (DPI), effective to protect NK cell and cytotoxic lymphocyte function in the presence of MO.

Don't
enter
882 B1
1/10/03